Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents

S. Reisinger, Keith; L. Block, Stan; Lazcano‐Ponce, Eduardo; Samakoses, Rudiwilai; T. Esser, Mark; Erick, Joanne; Puchalski, Derek; Giacoletti, Katherine; L. Sings, Heather; Lukac, Suzanne; B. Alvarez, Frances; Barr, Eliav

doi:10.1097/01.inf.0000253970.29190.5a

Public

Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents

Published in The Pediatric Infectious Disease Journal • Feb 27, 2007

Authors:

Keith S. Reisinger

Stan L. Block

Eduardo Lazcano‐Ponce

Abstract

OBJECTIVE: Administration of a quadrivalent HPV-6/ 1/16/18 vaccine to 16- to 26-year-old women was highly effective in preventing HPV-6/ 1/16/18-related cervical/vulvar/vaginal precancerous lesions and genital warts. As the risk of acquiring HPV significantly rises after sexual debut, HPV vaccines s...

Subject

Immunogenicity

Virology

Virus-like particle

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!